Stepping in the right direction but still some ways to go

Alfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender


Over the last few years we have witnessed substantial advances in systemic treatment of non-small cell lung cancer (NSCLC) patients harboring anaplastic lymphoma kinase gene rearrangements (ALK+ NSCLC) (ref). Multiple ALK inhibitors (ALKi) have been approved (alectinib, lorlatinib, brigatinib, ceritinib, crizotinib). Despite the survival benefit of all of these drugs, all patients with ALK+ NSCLC will inevitably progress at some point during their treatment (my review). Given the increased number of therapeutic options, understanding the resistance mechanism appears to be increasingly important.